Innovation PotentialAura Biosciences, Inc.BATS:AURAForexCompanyInnovation Potential: If bel-sar achieves approval and enters the market, this could lead to significant upside. Clinical Progress: The company is now in Phase 3 for one of its key indications, which is progress for a small biotech company. Aura Biosciences +1 Financial Liquidity: As of Q2 2025, Aura reports cash, equivalents, and liquid investments of approximately $177.3 million, after raising through a capital offering. Nasdaq Analyst Rating: According to StockAnalysis, the average target price is ~$22.29 per share (~+260% potential from the current price of ~$6.16 as of October 2025) StockAnalysis